Free Trial
NASDAQ:RYTM

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

$42.27
+2.15 (+5.36%)
(As of 06/12/2024 ET)
Today's Range
$40.95
$42.88
50-Day Range
$35.41
$43.88
52-Week Range
$15.50
$52.57
Volume
636,099 shs
Average Volume
603,214 shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.33

Rhythm Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
28.5% Upside
$54.33 Price Target
Short Interest
Bearish
17.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
1.23mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$3.92 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.44) to ($2.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.32 out of 5 stars

Medical Sector

289th out of 913 stocks

Pharmaceutical Preparations Industry

133rd out of 429 stocks

RYTM stock logo

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Stock Price History

RYTM Stock News Headlines

Rhythm Pharmaceuticals, Inc. (RYTM)
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call
The 3 Best Nasdaq Stocks to Buy in May 2024
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
6/12/2024
Next Earnings (Estimated)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RYTM
Employees
226
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$54.33
High Stock Price Target
$79.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+28.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-184,680,000.00
Net Margins
-297.91%
Pretax Margin
-296.99%

Debt

Sales & Book Value

Annual Sales
$91.93 million
Book Value
$2.87 per share

Miscellaneous

Free Float
57,559,000
Market Cap
$2.58 billion
Optionable
Optionable
Beta
1.93
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

RYTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price target for 2024?

6 analysts have issued 12-month price objectives for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $42.00 to $79.00. On average, they expect the company's stock price to reach $54.33 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2024?

Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of the year. Since then, RYTM stock has decreased by 8.0% and is now trading at $42.27.
View the best growth stocks for 2024 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its earnings results on Tuesday, May, 7th. The company reported ($2.35) earnings per share for the quarter, missing the consensus estimate of ($2.34) by $0.01. The firm had revenue of $26 million for the quarter, compared to analysts' expectations of $26.90 million. Rhythm Pharmaceuticals had a negative net margin of 297.91% and a negative trailing twelve-month return on equity of 179.26%. The company's revenue was up 126.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.92) EPS.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.42%), Healthcare of Ontario Pension Plan Trust Fund (1.20%), Janus Henderson Group PLC (1.02%), Canada Pension Plan Investment Board (0.95%), Opaleye Management Inc. (0.84%) and Price T Rowe Associates Inc. MD (0.79%). Insiders that own company stock include Christopher Paul German, David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RYTM) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners